<DOC>
	<DOCNO>NCT00157196</DOCNO>
	<brief_summary>The primary objective document safety tecemotide ( L-BLP25 ) phase III formulation non-small cell lung cancer ( NSCLC ) subject unresectable Stage III disease . This population include Stage IIIA NSCLC subject , population study former clinical study vaccine . The secondary objective document survival subject treat .</brief_summary>
	<brief_title>Safety Study Tecemotide ( L-BLP25 ) Non-Small Cell Lung Cancer ( NSCLC ) Subjects With Unresectable Stage III Disease</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Histologically document unresectable stage III NSCLC . Mediastinal ( N2 ) involvement must confirm biopsy Stable disease clinical response primary therapy chemoradiation treatment unresectable stage III disease Primary therapy minimum 2 cycle Platinumbased firstline chemotherapy , give concurrent thoracic radiation . The combined modality consist either : induction ( 2 cycle ) chemotherapy follow concurrent chemoradiation therapy ; concurrent chemoradiation therapy follow 2 cycle consolidation chemotherapy ; concurrent chemoradiation therapy alone A minimum radiation dose great equal ( &gt; = ) 6,000 centigray ( cGy ) administer . Subjects must complete primary therapy least 4 week later 6 month prior study entry Eastern Cooperative Oncology Group ( ECOG ) performance status less equal ( &lt; = ) 1 Ability understand willingness sign write informed consent Other protocol define inclusion criterion could apply Undergone lung cancer specific therapy ( include surgery ) prior primary chemoradiation therapy Received immunotherapy/systemic immunosuppressive drugs/investigational systemic drug within 4 week prior study entry Subjects brain metastasis , pleural effusion , unless cytologically confirm nonmalignant Past current history neoplasm lung carcinoma , except curatively treat nonmelanoma skin cancer , situ carcinoma cervix cancer curatively treat evidence disease least 5 year Autoimmune disease immunodeficiency Clinically significant hepatic , renal dysfunction cardiac diseases Clinically significant active infection Pregnant lactating , woman childbearing potential , unless use effective contraception determine investigator Other protocol define inclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Carcinoma , Non-Small-Cell Lung , L-BLP25 , Tecemotide</keyword>
</DOC>